Back to Search
Start Over
Biomarqueurs inflammatoires et immunologiques de réponse à la radiothérapie
- Source :
- Cancer/Radiothérapie. 22:180-192
- Publication Year :
- 2018
- Publisher :
- Elsevier BV, 2018.
-
Abstract
- In radiotherapy, the treatment is adapted to each individual to protect healthy tissues but delivers most of time a standard dose according to the tumor histology and site. The only biomarkers studied to individualize the treatment are the HPV status with radiation dose de-escalation strategies, and tumor hypoxia with dose escalation to hypoxic subvolumes using FMISO- or FAZA-PET imaging. In the last decades, evidence has grown about the contribution of the immune system to radiation tumor response. Many preclinical studies have identified some of the mechanisms involved. In this context, we have realised a systematic review to highlight potential inflammatory and immune biomarkers of radiotherapy response. Some are inside the tumor microenvironment, as lymphocyte infiltration or PD-L1 expression, others are circulating biomarkers, including different types of hematological cells, cytokines and chemokines.
- Subjects :
- 0301 basic medicine
Tumor microenvironment
Chemokine
Tumor hypoxia
biology
business.industry
medicine.medical_treatment
Context (language use)
Radiation therapy
03 medical and health sciences
Circulating biomarkers
030104 developmental biology
0302 clinical medicine
Immune system
Oncology
030220 oncology & carcinogenesis
Cancer research
biology.protein
Medicine
Radiology, Nuclear Medicine and imaging
business
FMISO
Subjects
Details
- ISSN :
- 12783218
- Volume :
- 22
- Database :
- OpenAIRE
- Journal :
- Cancer/Radiothérapie
- Accession number :
- edsair.doi.dedup.....9c230839cdef6c48f101ffa6c8542b57
- Full Text :
- https://doi.org/10.1016/j.canrad.2017.09.007